Arrowhead Pharmaceuticals · 2 weeks ago
Associate Manufacturing Scientist I (2nd shift)
Arrowhead Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative drugs for diseases with a genetic basis. The Associate Manufacturing Scientist I will assist in the synthesis and purification of large scale oligonucleotides while complying with GLP/GMP protocols and documenting operations.
BiotechnologyHealth CareNanotechnologyPharmaceutical
Responsibilities
Follow batch records, SOPs, and work instructions to detail
Document all operations in batch records and notebooks
Comply with GMP protocols
Assist other chemists within the CMC group during synthesis and chromatography of oligonucleotides including:
Reagent solution preparation
Column Packing
Mobile phase preparation
Fraction collection
Operate TFF to desalt purified RNA solutions
Operate a lyophilizer and package solid drug substance
Execute processes as part of a team to ensure production timelines are kept and quality product is produced
Maintain a clean work space
Maintain safety by wearing required personal protective equipment
Qualification
Required
Bachelor's degree in chemistry, biochemistry, engineering, or related scientific field
Experience working in a GMP setting and controlled documentation
Good verbal and written communication skills
Ability to work in a team environment
Ability to pay attention to detail
Benefits
Competitive salaries
Excellent benefit package
Company
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
H1B Sponsorship
Arrowhead Pharmaceuticals has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (4)
2024 (5)
2023 (1)
2022 (5)
2020 (1)
Funding
Current Stage
Public CompanyTotal Funding
$2.45BKey Investors
Sarepta TherapeuticsSixth StreetSilence Therapeutics
2026-01-07Post Ipo Equity· $200M
2026-01-07Post Ipo Debt· $625M
2024-11-26Post Ipo Equity· $325M
Leadership Team
Recent News
2026-01-08
Company data provided by crunchbase